Carsten A. WagnerInstitute of Physiology, University of Zurich, Winterthurerstrasse, Zurich, Switzerland National Center of Competence in Research Kidney Control of Homeostasis, Zurich, Switzerland
VoelklJ, Egli-SpichtigD, AlesutanI, WagnerCA: Inflammation: A putative link between phosphate metabolism and cardiovascular disease. Clin Sci (Lond)135: 201–227, 2021PubMed
VoelklJ, Egli-SpichtigD, AlesutanI, WagnerCA: Inflammation: A putative link between phosphate metabolism and cardiovascular disease. Clin Sci (Lond) 135: 201–227, 2021PubMed)| false
MohammadJ, ScanniR, BestmannL, HulterHN, KrapfR: A controlled increase in dietary phosphate elevates BP in healthy human subjects. J Am Soc Nephrol29: 2089–2098, 2018PubMed
MohammadJ, ScanniR, BestmannL, HulterHN, KrapfR: A controlled increase in dietary phosphate elevates BP in healthy human subjects. J Am Soc Nephrol 29: 2089–2098, 2018PubMed)| false
ScanniR, vonRotzM, JehleS, HulterHN, KrapfR: The human response to acute enteral and parenteral phosphate loads. J Am Soc Nephrol25: 2730–2739, 2014PubMed
ScanniR, vonRotzM, JehleS, HulterHN, KrapfR: The human response to acute enteral and parenteral phosphate loads. J Am Soc Nephrol 25: 2730–2739, 2014PubMed)| false
BourgeoisS, CapuanoP, StangeG, MühlemannR, MurerH, BiberJ, et al.: The phosphate transporter NaPi-IIa determines the rapid renal adaptation to dietary phosphate intake in mouse irrespective of persistently high FGF23 levels. Pflugers Arch465: 1557–1572, 2013PubMed
BourgeoisS, CapuanoP, StangeG, MühlemannR, MurerH, BiberJ, et al.: The phosphate transporter NaPi-IIa determines the rapid renal adaptation to dietary phosphate intake in mouse irrespective of persistently high FGF23 levels. Pflugers Arch 465: 1557–1572, 2013PubMed)| false
GiralH, CaldasY, SutherlandE, WilsonP, BreusegemS, BarryN, et al.: Regulation of rat intestinal Na-dependent phosphate transporters by dietary phosphate. Am J Physiol Renal Physiol297: F1466–F1475, 2009PubMed
GiralH, CaldasY, SutherlandE, WilsonP, BreusegemS, BarryN, et al.: Regulation of rat intestinal Na-dependent phosphate transporters by dietary phosphate. Am J Physiol Renal Physiol 297: F1466–F1475, 2009PubMed)| false
HernandoN, Pastor-ArroyoEM, MarksJ, SchnitzbauerU, KnöpfelT, BürkiM, et al.: 1,25(OH)2 vitamin D3 stimulates active phosphate transport but not paracellular phosphate absorption in mouse intestine. J Physiol599: 1131–1150, 2021PubMed
HernandoN, Pastor-ArroyoEM, MarksJ, SchnitzbauerU, KnöpfelT, BürkiM, et al.: 1,25(OH)2 vitamin D3 stimulates active phosphate transport but not paracellular phosphate absorption in mouse intestine. J Physiol 599: 1131–1150, 2021PubMed)| false
Pastor-ArroyoEM, KnöpfelT, Imenez SilvaPH, SchnitzbauerU, PoncetN, BiberJ, et al.: Intestinal epithelial ablation of Pit-2/Slc20a2 in mice leads to sustained elevation of vitamin D3 upon dietary restriction of phosphate. Acta Physiol (Oxf)230: e13526, 2020PubMed
Pastor-ArroyoEM, KnöpfelT, Imenez SilvaPH, SchnitzbauerU, PoncetN, BiberJ, et al.: Intestinal epithelial ablation of Pit-2/Slc20a2 in mice leads to sustained elevation of vitamin D3 upon dietary restriction of phosphate. Acta Physiol (Oxf) 230: e13526, 2020PubMed)| false
IchidaY, OhtomoS, YamamotoT, MuraoN, TsuboiY, KawabeY, et al.: Evidence of an intestinal phosphate transporter alternative to type IIb sodium-dependent phosphate transporter in rats with chronic kidney disease. Nephrol Dial Transplant36: 68–75, 2021PubMed
IchidaY, OhtomoS, YamamotoT, MuraoN, TsuboiY, KawabeY, et al.: Evidence of an intestinal phosphate transporter alternative to type IIb sodium-dependent phosphate transporter in rats with chronic kidney disease. Nephrol Dial Transplant 36: 68–75, 2021PubMed)| false
KingAJ, SiegelM, HeY, NieB, WangJ, Koo-McCoyS, et al.: Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability. Sci Transl Med10: eaam6474, 2018PubMed
KingAJ, SiegelM, HeY, NieB, WangJ, Koo-McCoyS, et al.: Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability. Sci Transl Med 10: eaam6474, 2018PubMed)| false
BlockGA, BleyerAJ, SilvaAL, WeinerDE, LynnRI, YangY, et al.: Safety and efficacy of tenapanor for long-term serum phosphate control in maintenance dialysis: A 52-week randomized phase 3 trial (PHREEDOM). Kidney3602: 1600–1610, 2021PubMed
BlockGA, BleyerAJ, SilvaAL, WeinerDE, LynnRI, YangY, et al.: Safety and efficacy of tenapanor for long-term serum phosphate control in maintenance dialysis: A 52-week randomized phase 3 trial (PHREEDOM). Kidney360 2: 1600–1610, 2021PubMed)| false
WagnerCA: Coming out of the PiTs-novel strategies for controlling intestinal phosphate absorption in patients with CKD. Kidney Int98: 273–275, 2020PubMed
WagnerCA: Coming out of the PiTs-novel strategies for controlling intestinal phosphate absorption in patients with CKD. Kidney Int 98: 273–275, 2020PubMed)| false
MottaSE, Imenez SilvaPH, DaryadelA, HaykirB, Pastor-ArroyoEM, BettoniC, et al.: Expression of NaPi-IIb in rodent and human kidney and upregulation in a model of chronic kidney disease. Pflugers Arch472: 449–460, 2020PubMed
MottaSE, Imenez SilvaPH, DaryadelA, HaykirB, Pastor-ArroyoEM, BettoniC, et al.: Expression of NaPi-IIb in rodent and human kidney and upregulation in a model of chronic kidney disease. Pflugers Arch 472: 449–460, 2020PubMed)| false
AnheimM, López-SánchezU, GiovanniniD, RichardAC, TouhamiJ, N’GuyenL, et al.: XPR1 mutations are a rare cause of primary familial brain calcification. J Neurol263: 1559–1564, 2016PubMed
AnheimM, López-SánchezU, GiovanniniD, RichardAC, TouhamiJ, N’GuyenL, et al.: XPR1 mutations are a rare cause of primary familial brain calcification. J Neurol 263: 1559–1564, 2016PubMed)| false
AnsermetC, MoorMB, CentenoG, AubersonM, HuDZ, BaronR, et al.: Renal fanconi syndrome and hypophosphatemic rickets in the absence of xenotropic and polytropic retroviral receptor in the nephron. J Am Soc Nephrol28: 1073–1078, 2017PubMed
AnsermetC, MoorMB, CentenoG, AubersonM, HuDZ, BaronR, et al.: Renal fanconi syndrome and hypophosphatemic rickets in the absence of xenotropic and polytropic retroviral receptor in the nephron. J Am Soc Nephrol 28: 1073–1078, 2017PubMed)| false
BacicD, LehirM, BiberJ, KaisslingB, MurerH, WagnerCA: The renal Na+/phosphate cotransporter NaPi-IIa is internalized via the receptor-mediated endocytic route in response to parathyroid hormone. Kidney Int69: 495–503, 2006PubMed
BacicD, LehirM, BiberJ, KaisslingB, MurerH, WagnerCA: The renal Na+/phosphate cotransporter NaPi-IIa is internalized via the receptor-mediated endocytic route in response to parathyroid hormone. Kidney Int 69: 495–503, 2006PubMed)| false
LedererE, WagnerCA: Clinical aspects of the phosphate transporters NaPi-IIa and NaPi-IIb: Mutations and disease associations. Pflugers Arch471: 137–148, 2019PubMed
LedererE, WagnerCA: Clinical aspects of the phosphate transporters NaPi-IIa and NaPi-IIb: Mutations and disease associations. Pflugers Arch 471: 137–148, 2019PubMed)| false
MagenD, BergerL, CoadyMJ, IlivitzkiA, MilitianuD, TiederM, et al.: A loss-of-function mutation in NaPi-IIa and renal Fanconi’s syndrome. N Engl J Med362: 1102–1109, 2010PubMed
MagenD, BergerL, CoadyMJ, IlivitzkiA, MilitianuD, TiederM, et al.: A loss-of-function mutation in NaPi-IIa and renal Fanconi’s syndrome. N Engl J Med 362: 1102–1109, 2010PubMed)| false
DasguptaD, WeeMJ, ReyesM, LiY, SimmPJ, SharmaA, et al.: Mutations in SLC34A3/NPT2c are associated with kidney stones and nephrocalcinosis. J Am Soc Nephrol25: 2366–2375, 2014PubMed
DasguptaD, WeeMJ, ReyesM, LiY, SimmPJ, SharmaA, et al.: Mutations in SLC34A3/NPT2c are associated with kidney stones and nephrocalcinosis. J Am Soc Nephrol 25: 2366–2375, 2014PubMed)| false
Haito-SuginoS, ItoM, OhiA, ShiozakiY, KangawaN, NishiyamaT, et al.: Processing and stability of type IIc sodium-dependent phosphate cotransporter mutations in patients with hereditary hypophosphatemic rickets with hypercalciuria. Am J Physiol Cell Physiol302: C1316–C1330, 2012PubMed
Haito-SuginoS, ItoM, OhiA, ShiozakiY, KangawaN, NishiyamaT, et al.: Processing and stability of type IIc sodium-dependent phosphate cotransporter mutations in patients with hereditary hypophosphatemic rickets with hypercalciuria. Am J Physiol Cell Physiol 302: C1316–C1330, 2012PubMed)| false
AmarA, MajmundarAJ, UllahI, AfzalA, BraunDA, ShrilS, et al.: Gene panel sequencing identifies a likely monogenic cause in 7% of 235 Pakistani families with nephrolithiasis. Hum Genet138: 211–219, 2019PubMed
AmarA, MajmundarAJ, UllahI, AfzalA, BraunDA, ShrilS, et al.: Gene panel sequencing identifies a likely monogenic cause in 7% of 235 Pakistani families with nephrolithiasis. Hum Genet 138: 211–219, 2019PubMed)| false
BraunDA, LawsonJA, GeeHY, HalbritterJ, ShrilS, TanW, et al.: Prevalence of monogenic causes in pediatric patients with nephrolithiasis or nephrocalcinosis. Clin J Am Soc Nephrol11: 664–672, 2016PubMed
BraunDA, LawsonJA, GeeHY, HalbritterJ, ShrilS, TanW, et al.: Prevalence of monogenic causes in pediatric patients with nephrolithiasis or nephrocalcinosis. Clin J Am Soc Nephrol 11: 664–672, 2016PubMed)| false
DagaA, MajmundarAJ, BraunDA, GeeHY, LawsonJA, ShrilS, et al.: Whole exome sequencing frequently detects a monogenic cause in early onset nephrolithiasis and nephrocalcinosis. Kidney Int93: 204–213, 2018PubMed
DagaA, MajmundarAJ, BraunDA, GeeHY, LawsonJA, ShrilS, et al.: Whole exome sequencing frequently detects a monogenic cause in early onset nephrolithiasis and nephrocalcinosis. Kidney Int 93: 204–213, 2018PubMed)| false
KöttgenA, PattaroC, BögerCA, FuchsbergerC, OldenM, GlazerNL, et al.: New loci associated with kidney function and chronic kidney disease. Nat Genet42: 376–384, 2010PubMed
KöttgenA, PattaroC, BögerCA, FuchsbergerC, OldenM, GlazerNL, et al.: New loci associated with kidney function and chronic kidney disease. Nat Genet 42: 376–384, 2010PubMed)| false
KöttgenA, GlazerNL, DehghanA, HwangSJ, KatzR, LiM, et al.: Multiple loci associated with indices of renal function and chronic kidney disease. Nat Genet41: 712–717, 2009PubMed
KöttgenA, GlazerNL, DehghanA, HwangSJ, KatzR, LiM, et al.: Multiple loci associated with indices of renal function and chronic kidney disease. Nat Genet 41: 712–717, 2009PubMed)| false
OddssonA, SulemP, HelgasonH, EdvardssonVO, ThorleifssonG, SveinbjörnssonG, et al.: Common and rare variants associated with kidney stones and biochemical traits. Nat Commun6: 7975, 2015PubMed
OddssonA, SulemP, HelgasonH, EdvardssonVO, ThorleifssonG, SveinbjörnssonG, et al.: Common and rare variants associated with kidney stones and biochemical traits. Nat Commun 6: 7975, 2015PubMed)| false
KarimZ, GérardB, BakouhN, AliliR, LeroyC, BeckL, et al.: NHERF1 mutations and responsiveness of renal parathyroid hormone. N Engl J Med359: 1128–1135, 2008PubMed
KarimZ, GérardB, BakouhN, AliliR, LeroyC, BeckL, et al.: NHERF1 mutations and responsiveness of renal parathyroid hormone. N Engl J Med 359: 1128–1135, 2008PubMed)| false
BhandaruM, KempeDS, RotteA, CapuanoP, PathareG, SopjaniM, et al.: Decreased bone density and increased phosphaturia in gene-targeted mice lacking functional serum- and glucocorticoid-inducible kinase 3. Kidney Int80: 61–67, 2011PubMed
BhandaruM, KempeDS, RotteA, CapuanoP, PathareG, SopjaniM, et al.: Decreased bone density and increased phosphaturia in gene-targeted mice lacking functional serum- and glucocorticoid-inducible kinase 3. Kidney Int 80: 61–67, 2011PubMed)| false
CirilloM, CiacciC, De SantoNG: Age, renal tubular phosphate reabsorption, and serum phosphate levels in adults. N Engl J Med359: 864–866, 2008PubMed
CirilloM, CiacciC, De SantoNG: Age, renal tubular phosphate reabsorption, and serum phosphate levels in adults. N Engl J Med 359: 864–866, 2008PubMed)| false
VervloetMG, SezerS, MassyZA, JohanssonL, CozzolinoM, FouqueD; ERA–EDTA Working Group on Chronic Kidney Disease–Mineral and Bone Disorders and the European Renal Nutrition Working Group: The role of phosphate in kidney disease. Nat Rev Nephrol13: 27–38, 2017PubMed
VervloetMG, SezerS, MassyZA, JohanssonL, CozzolinoM, FouqueD; ERA–EDTA Working Group on Chronic Kidney Disease–Mineral and Bone Disorders and the European Renal Nutrition Working Group: The role of phosphate in kidney disease. Nat Rev Nephrol 13: 27–38, 2017PubMed)| false
YooKD, KangS, ChoiY, YangSH, HeoNJ, ChinHJ, et al.: Sex, age, and the association of serum phosphorus with all-cause mortality in adults with normal kidney function. Am J Kidney Dis67: 79–88, 2016PubMed
YooKD, KangS, ChoiY, YangSH, HeoNJ, ChinHJ, et al.: Sex, age, and the association of serum phosphorus with all-cause mortality in adults with normal kidney function. Am J Kidney Dis 67: 79–88, 2016PubMed)| false
TonelliM, SacksF, PfefferM, GaoZ, CurhanG; Cholesterol And Recurrent Events Trial Investigators: Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation112: 2627–2633, 2005PubMed
TonelliM, SacksF, PfefferM, GaoZ, CurhanG; Cholesterol And Recurrent Events Trial Investigators: Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 112: 2627–2633, 2005PubMed)| false
DhingraR, GonaP, BenjaminEJ, WangTJ, AragamJ, D’AgostinoRBSr, et al.: Relations of serum phosphorus levels to echocardiographic left ventricular mass and incidence of heart failure in the community. Eur J Heart Fail12: 812–818, 2010PubMed
DhingraR, GonaP, BenjaminEJ, WangTJ, AragamJ, D’AgostinoRBSr, et al.: Relations of serum phosphorus levels to echocardiographic left ventricular mass and incidence of heart failure in the community. Eur J Heart Fail 12: 812–818, 2010PubMed)| false
SimJJ, BhandariSK, SmithN, ChungJ, LiuIL, JacobsenSJ, et al.: Phosphorus and risk of renal failure in subjects with normal renal function. Am J Med126: 311–318, 2013PubMed
SimJJ, BhandariSK, SmithN, ChungJ, LiuIL, JacobsenSJ, et al.: Phosphorus and risk of renal failure in subjects with normal renal function. Am J Med 126: 311–318, 2013PubMed)| false
ChangAR, LazoM, AppelLJ, GutiérrezOM, GramsME: High dietary phosphorus intake is associated with all-cause mortality: Results from NHANES III. Am J Clin Nutr99: 320–327, 2014PubMed
ChangAR, LazoM, AppelLJ, GutiérrezOM, GramsME: High dietary phosphorus intake is associated with all-cause mortality: Results from NHANES III. Am J Clin Nutr 99: 320–327, 2014PubMed)| false
PavikI, JaegerP, EbnerL, WagnerCA, PetzoldK, SpichtigD, et al.: Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: a sequence suggested from a cross-sectional study. Nephrol Dial Transplant28: 352–359, 2013PubMed
PavikI, JaegerP, EbnerL, WagnerCA, PetzoldK, SpichtigD, et al.: Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: a sequence suggested from a cross-sectional study. Nephrol Dial Transplant 28: 352–359, 2013PubMed)| false
IsakovaT, WahlP, VargasGS, GutiérrezOM, SciallaJ, XieH, et al.: Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int79: 1370–1378, 2011PubMed
IsakovaT, WahlP, VargasGS, GutiérrezOM, SciallaJ, XieH, et al.: Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 79: 1370–1378, 2011PubMed)| false
HuMC, ShiizakiK, Kuro-oM, MoeOW: Fibroblast growth factor 23 and Klotho: Physiology and pathophysiology of an endocrine network of mineral metabolism. Annu Rev Physiol75: 503–533, 2013PubMed
HuMC, ShiizakiK, Kuro-oM, MoeOW: Fibroblast growth factor 23 and Klotho: Physiology and pathophysiology of an endocrine network of mineral metabolism. Annu Rev Physiol 75: 503–533, 2013PubMed)| false
DhayatNA, AckermannD, PruijmM, PonteB, EhretG, GuessousI, et al.: Fibroblast growth factor 23 and markers of mineral metabolism in individuals with preserved renal function. Kidney Int90: 648–657, 2016PubMed
DhayatNA, AckermannD, PruijmM, PonteB, EhretG, GuessousI, et al.: Fibroblast growth factor 23 and markers of mineral metabolism in individuals with preserved renal function. Kidney Int 90: 648–657, 2016PubMed)| false
Durlacher-BetzerK, HassanA, LeviR, AxelrodJ, SilverJ, Naveh-ManyT: Interleukin-6 contributes to the increase in fibroblast growth factor 23 expression in acute and chronic kidney disease. Kidney Int94: 315–325, 2018PubMed
Durlacher-BetzerK, HassanA, LeviR, AxelrodJ, SilverJ, Naveh-ManyT: Interleukin-6 contributes to the increase in fibroblast growth factor 23 expression in acute and chronic kidney disease. Kidney Int 94: 315–325, 2018PubMed)| false
SimicP, KimW, ZhouW, PierceKA, ChangW, SykesDB, et al.: Glycerol-3-phosphate is an FGF23 regulator derived from the injured kidney. J Clin Invest130: 1513–1526, 2020PubMed
SimicP, KimW, ZhouW, PierceKA, ChangW, SykesDB, et al.: Glycerol-3-phosphate is an FGF23 regulator derived from the injured kidney. J Clin Invest 130: 1513–1526, 2020PubMed)| false
MarthiA, DonovanK, HaynesR, WheelerDC, BaigentC, RooneyCM, et al.: Fibroblast growth factor-23 and risks of cardiovascular and noncardiovascular diseases: A meta-analysis. J Am Soc Nephrol29: 2015–2027, 2018PubMed
MarthiA, DonovanK, HaynesR, WheelerDC, BaigentC, RooneyCM, et al.: Fibroblast growth factor-23 and risks of cardiovascular and noncardiovascular diseases: A meta-analysis. J Am Soc Nephrol 29: 2015–2027, 2018PubMed)| false
WagnerCA, Rubio-AliagaI, Egli-SpichtigD: Fibroblast growth factor 23 in chronic kidney disease: What is its role in cardiovascular disease?Nephrol Dial Transplant34: 1986–1990, 2019PubMed
WagnerCA, Rubio-AliagaI, Egli-SpichtigD: Fibroblast growth factor 23 in chronic kidney disease: What is its role in cardiovascular disease?Nephrol Dial Transplant 34: 1986–1990, 2019PubMed)| false
Pastor-ArroyoEM, GehringN, KrudewigC, CostantinoS, BettoniC, KnöpfelT, et al.: The elevation of circulating fibroblast growth factor 23 without kidney disease does not increase cardiovascular disease risk. Kidney Int94: 49–59, 2018PubMed
Pastor-ArroyoEM, GehringN, KrudewigC, CostantinoS, BettoniC, KnöpfelT, et al.: The elevation of circulating fibroblast growth factor 23 without kidney disease does not increase cardiovascular disease risk. Kidney Int 94: 49–59, 2018PubMed)| false
PergolaPE, RosenbaumDP, YangY, ChertowGM: A randomized trial of tenapanor and phosphate binders as a dual-mechanism treatment for hyperphosphatemia in patients on maintenance dialysis (AMPLIFY). JASN32: 1465–1473, 2021PubMed
PergolaPE, RosenbaumDP, YangY, ChertowGM: A randomized trial of tenapanor and phosphate binders as a dual-mechanism treatment for hyperphosphatemia in patients on maintenance dialysis (AMPLIFY). JASN 32: 1465–1473, 2021PubMed)| false
